Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | MMP8 | P22894 | 2/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 4/20 | 0.37 |
| ▸ | CTSD | P07339 | 2/20 | 0.36 |
| ▸ | ARG1 | P05089 | 1/20 | 0.36 |
| ▸ | ARG2 | P78540 | 1/20 | 0.36 |
| ▸ | REN | P00797 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL84090 | 1.00 | CYP1A2 (0.47) | CYP1A2CYP3A4MMP8MMP1BCHE | |
| SCHEMBL84091 | 1.00 | CYP1A2 (0.47) | CYP1A2CYP3A4MMP8MMP1BCHE | |
| SCHEMBL81994 | 0.92 | CYP1A2 (0.43) | CYP1A2CYP3A4MMP8MMP1BCHE | |
| SCHEMBL81993 | 0.92 | CYP1A2 (0.43) | CYP1A2CYP3A4MMP8MMP1BCHE | |
| SCHEMBL81992 | 0.92 | CYP1A2 (0.43) | CYP1A2CYP3A4MMP8MMP1BCHE | |
| SCHEMBL13004350 | 0.92 | CYP1A2 (0.43) | CYP1A2CYP3A4MMP8MMP1BCHE | |
| SCHEMBL81030 | 0.89 | CYP1A2 (0.51) | CYP1A2CYP3A4MMP8MMP1BCHE | |
| SCHEMBL81031 | 0.89 | CYP1A2 (0.51) | CYP1A2CYP3A4MMP8MMP1BCHE | |
| SCHEMBL81032 | 0.89 | CYP1A2 (0.51) | CYP1A2CYP3A4MMP8MMP1BCHE | |
| SCHEMBL83288 | 0.89 | CYP1A2 (0.51) | CYP1A2CYP3A4MMP8MMP1BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183231-B2 | Substituted propane phosphinic acid derivatives | AVENTIS PHARMACEUTICALS INC. (US) | 2012-05-22 | — | — | US | claimed |
| JP-4813469-B2 | — | — | 2011-11-09 | — | — | JP | claimed |
| EP-1765850-B1 | SUBSTITUTED PROPANE PHOSPHINIC ACID DERIVATIVES | AVENTIS PHARMA INC (US) | 2010-12-01 | — | — | EP | claimed |
| JP-2008503448-A | — | — | 2008-02-07 | — | — | JP | claimed |
| EP-1765850-A1 | SUBSTITUTED PROPANE PHOSPHINIC ACID DERIVATIVES | Aventis Pharmaceuticals, Inc. (US) | 2007-03-28 | — | — | EP | claimed |
| US-20070060502-A1 | SUBSTITUTED PROPANE PHOSPHINIC ACID DERIVATIVES | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-15 | — | — | US | claimed |
| WO-2005118618-A1 | SUBSTITUTED PROPANE PHOSPHINIC ACID DERIVATIVES | AVENTIS PHARMACEUTICALS INC. (US) | 2005-12-15 | — | — | WO | claimed |
| US-8828974-B2 | Substituted propane phosphinic acid derivatives | AVENTIS PHARMACEUTICALS INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-20120208784-A1 | SUBSTITUTED PROPANE PHOSPHINIC ACID DERIVATIVES | AVENTIS PHARMACEUTICALS INC. (US) | 2012-08-16 | — | — | US | disclosed |
| US-8183231-B2 | Substituted propane phosphinic acid derivatives | AVENTIS PHARMACEUTICALS INC. (US) | 2012-05-22 | — | — | US | disclosed |
| EP-1765850-B1 | SUBSTITUTED PROPANE PHOSPHINIC ACID DERIVATIVES | AVENTIS PHARMA INC (US) | 2010-12-01 | — | — | EP | disclosed |
| EP-1765850-A1 | SUBSTITUTED PROPANE PHOSPHINIC ACID DERIVATIVES | Aventis Pharmaceuticals, Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| US-20070060502-A1 | SUBSTITUTED PROPANE PHOSPHINIC ACID DERIVATIVES | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-15 | — | — | US | disclosed |
| WO-2005118618-A1 | SUBSTITUTED PROPANE PHOSPHINIC ACID DERIVATIVES | AVENTIS PHARMACEUTICALS INC. (US) | 2005-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060502-A1 | SUBSTITUTED PROPANE PHOSPHINIC ACID DERIVATIVES | PHOSPHO1, PTEN, PLCB1 | CYP1A2 3286/4885CYP3A4 4499/4885MMP8 4848/4885 |
| US-20120208784-A1 | SUBSTITUTED PROPANE PHOSPHINIC ACID DERIVATIVES | PHOSPHO1, PTEN, PLCB1 | CYP1A2 3286/4885CYP3A4 4499/4885MMP8 4848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.